John Oyler, CEO of ONC (Oncology Company), has demonstrated a pronounced selling bias in his recent insider transactions, with no open-market purchases recorded in the latest filings. Over his tenure, Oyler has executed 52 trades exclusively in ONC stock, with a stark imbalance between buying and selling activity—$650,000 in total buys compared to $50.5 million in total sales. The most recent transactions, concentrated in December 2025, involved 23 separate sales totaling over $26.7 million, with individual transactions ranging from $37,743 to $5.06 million. Notably, the largest single sale occurred on December 15, 2025, when Oyler disposed of shares worth $5.07 million, followed by another $4.37 million sale the same day. Two smaller transactions on March 6, 2026, were marked as derivative adjustments (Code A) with no reported value, suggesting they may involve option exercises or other non-open-market activity. The absence of recent buys and the scale of disposals—particularly the multi-million-dollar December 2025 sales—indicate a sustained reduction in Oyler’s ONC holdings. The activity is confined to a single company, with no diversification across other securities in the reported period.
AI-assisted summary